Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Sarcoma 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Melanoma 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 26Nivolumab 18enfortumab vedotin 7avelumab 6atezolizumab 6Ipilimumab 6Magnetic Resonance Spectroscopy 5fludarabine 4cabozantinib 4Gemcitabine 4Cyclophosphamide 4Carboplatin 4Specimen Handling 3Interleukin-2 3Docetaxel 3130-nm albumin-bound paclitaxel 3aldesleukin 2Platinum 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Immunoglobulin G 2Fluorodeoxyglucose F18 2FAPI-46 2Disulfides 2Cisplatin 2Albumin-Bound Paclitaxel 2vinflunine 1veliparib 1valrubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Transitional Cell × BCG Vaccine × Clear all
NCT00070070 2022-10-12

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Ludwig Institute for Cancer Research

Phase 1 Completed
6 enrolled 7 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡